

Active Research Studies at Corewell Health West

Pediatrics

Oncology

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Clinical Trial Number NCT04301843

A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma

Study acronym: MEMMAT (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial). Frequent delivery of low doses of chemotherapy, also known as metronomic or antiangiogenic therapy, targets endothelial cells while reducing the toxicity associated with standard dose chemo. This study evaluates the use of IV bevacizumab q2weeks in combo with five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose etoposide and cyclophosphamide), augmented with alternating courses of IT etoposide and cytarabine.

Head Start 4

Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors. Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to either Single-Cycle or to Three Sequential Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue

NMTRC014: NMTT-Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

To evaluate the efficacy of DFMO as a single agent in preventing relapse in patients with high-risk neuroblastoma who are in remission based upon EFS and OS from time of enrollment

For information about research studies listed please use these contacts below:

Email: researchassist@corewellhealth.org

Phone: 616-391-3050